Interleukin-19 blockade attenuates collagen-induced arthritis in rats

Rheumatology

Volumn 51, Issue 3, 2012, Pages 434-442

  Hsu, Yu Hsiang ^a   Hsieh, Pei Pei ^a   Chang, Ming Shi ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Collagen induced arthritis; IL 19; Synovial fibroblast

Indexed keywords

1 BB 1; ANTIRHEUMATIC AGENT; COLLAGEN; IMMUNOGLOBULIN G; INTERLEUKIN 19; INTERLEUKIN 19 MONOCLONAL ANTIBODY; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DENSITY; BONE DESTRUCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE CONTROL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTIBODIES, BLOCKING; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; X-RAY MICROTOMOGRAPHY;

EID: 84857551794     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker127     Document Type: Article

References (40)

1. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008;121:1108-11.
2. Gallagher G, Dickensheets H, Eskdale J et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000;1:442-50.
3. Hsing CH, Ho CL, Chang LY, Lee YL, Chuang SS, Chang MS. Tissue microarray analysis of interleukin-20 expression. Cytokine 2006;35:44-52.
4. Preimel D, Sticht H. Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family. J Mol Model 2004;10:290-6.
5. Parrish-Novak J, Xu W, Brender T et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002;277:47517-23.
6. Sakurai N, Kuroiwa T, Ikeuchi H et al. Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology 2008;47:815-20.
7. Hsing CH, Chiu CJ, Chang LY, Hsu CC, Chang MS. IL-19 is involved in the pathogenesis of endotoxic shock. Shock 2008;29:7-15.
8. Gallagher G, Eskdale J, Jordan W et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004;4: 615-26.
9. Liao SC, Cheng YC, Wang YC et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 2004;173:6712-8.
10. Li HH, Lin YC, Chen PJ et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 2005;153:591-5.
11. Alanara T, Karstila K, Moilanen T, Silvennoinen O, Isomaki P. Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints. Scand J Rheumatol 2010;39:118-26.
12. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
13. Feldmann M, Brennan FM, Williams RO et al. Evaluation of the role of cytokines in autoimmune disease: theimportance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res 1992;4:247-55.
14. Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:296-301.
15. Hsu YH, Li HH, Hsieh MY et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006;54:2722-33.
16. Li J, Sarosi I, Yan XQ et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97: 1566-71.
17. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
18. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
19. Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol 2002;65: 39-43.
20. Walmsley M, Katsikis PD, Abney E et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39: 495-503.
21. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
22. Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J. Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther 2003;5:R18-24.
23. Ikeuchi H, Kuroiwa T, Hiramatsu N et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52: 1037-46.
24. Hsing CH, Li HH, Hsu YH et al. The distribution of interleukin-19 in healthy and neoplastic tissue. Cytokine 2008;44:221-8.
25. Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001;103:407-16.
26. Lubberts E, van den Berg WB. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol 2003;520:194-202.
27. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118: 3537-45.
28. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
29. Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N. Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets 2008;7:53-66.
30. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
31. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21:75-87, discussion 71-2.
32. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006;23:208-17.
33. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;7: CD008331.
34. Marsal S, Julia A. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics 2010;11:617-9.
35. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
36. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009;5: 667-76.
37. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008;68:5803-11.
38. Park BK, Zhang H, Zeng Q et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13:62-9.
39. McClung MR. Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 2006;4:28-33.
40. Genant HK, Engelke K, Hanley DA et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010;47:131-9.